India Approves First Dengue Vaccine QDENGA for Ages 4-60!
India Approves First Dengue Vaccine QDENGA for Ages 4-60!
Historic news for public health! India's DCGI has cleared Takeda's QDENGA, the nation's first dengue vaccine, for individuals aged 4-60. A massive step in combating India's significant dengue burden. Get the details!
In a landmark decision set to significantly bolster public health efforts, India has officially approved its first-ever dengue vaccine. The Drug Controller General of India (DCGI) has given the green light to Takeda Biopharmaceuticals India's QDENGA, paving the way for its use in individuals aged 4 to 60 years under the New Drugs and Clinical Trials Rules, 2019.
This approval marks a pivotal moment, especially considering that India shoulders nearly one-third of the global dengue burden. The number of reported dengue cases in the country has surged dramatically, increasing eleven-fold over the past two decades. While official figures showed over 113,000 cases in recent years, expert modeling suggests the actual number of infections could be in the tens of millions annually, highlighting the urgent need for effective preventive measures.
QDENGA is a cutting-edge tetravalent, live-attenuated vaccine engineered to offer protection against all four serotypes of the dengue virus. A key advantage of this vaccine is that it can be administered regardless of an individual's prior dengue exposure and does not necessitate pre-vaccination testing. The vaccine is given as a two-dose regimen, with each 0.5 mL dose administered subcutaneously three months apart.
Dengue is notoriously difficult to manage due to the absence of a specific treatment. The disease can rapidly escalate, leading to severe complications that often require hospitalization and intensive care. The introduction of QDENGA offers a crucial tool in the fight against this debilitating mosquito-borne illness.
Globally, QDENGA has already garnered significant recognition. It is recommended by the World Health Organization (WHO) for use in dengue-endemic regions and is supported for integration into public immunization programs in areas with high transmission, again without the need for pre-vaccination screening. The vaccine has also achieved WHO pre-qualification, validating its quality, safety, and efficacy, and making it eligible for procurement by international bodies like UNICEF and PAHO. Since its launch in 2022, QDENGA has received approval in 43 countries across Asia, Latin America, and Europe, with more than 32 million doses already distributed worldwide through both public and private channels.
